Iowa Roundup Cancer Lawsuits After the Supreme Court Blocks Failure-to-Warn Claims
If you are reading this in Iowa — on a kitchen table in Muscatine, in a farm office outside Ames, in a hospital waiting room in Iowa City — you just heard that the Supreme Court ruled the maker of Roundup cannot be sued for failing to warn people that the weedkiller could cause cancer. And your first thought was probably: my case is dead. The agricultural organizations that lobbied for this outcome said it protects farmers. The company’s CEO called it “overdue justice.” Both candidates for Iowa governor called it a terrible decision. We are going to tell you what the ruling actually does, what it does not do, and why the path forward, while harder, is not closed.
The ruling blocks one legal theory — failure-to-warn based on the product label — under a federal pesticide law called FIFRA. It does not block every theory. Design defect claims, fraud claims, and negligent-testing claims target corporate conduct that has nothing to do with the label, and those doors remain open. The Iowa farmers, applicators, and rural families who have been breathing and handling glyphosate for decades deserve to know exactly what survives, what the evidence looks like, and what to do right now before the proof disappears. That is what this page is for. We are Attorney911 — The Manginello Law Firm, and we take toxic tort and catastrophic injury cases in Iowa. The consultation is free. We do not get paid unless we win your case. Call 1-888-ATTY-911, any hour.
What the Supreme Court Actually Ruled — and What It Did Not Block
The Supreme Court ruled that Monsanto — now owned by Bayer — cannot be sued under state law for failing to put a cancer warning on the Roundup label. The legal engine behind the ruling is FIFRA, the Federal Insecticide, Fungicide, and Rodenticide Act, which governs how pesticides are registered and labeled through the EPA. Under FIFRA’s preemption framework, state law requirements that are inconsistent with or different from the EPA-approved labeling are preempted. Bayer argued that because the EPA found glyphosate unlikely to cause cancer, the company was not permitted to include a cancer warning on the federally approved label. The Supreme Court agreed.
That is a serious blow. Failure-to-warn was the primary litigation theory behind thousands of Roundup cancer lawsuits nationwide. But here is what the ruling did not do. It did not find that glyphosate is safe. It did not find that Roundup does not cause cancer. It did not find that Monsanto acted properly. It did not block design defect claims, which argue the product itself was dangerously designed regardless of what the label said. It did not block fraud claims, which argue the company misrepresented the safety of glyphosate to regulators, the scientific community, or the public. It did not block negligent-testing claims, which argue the company failed to conduct adequate research or willfully ignored evidence of carcinogenicity. And it did not block claims against entities in the chain of distribution that may face strict product liability under theories that do not depend on the label content.
The science conflict at the heart of this case did not disappear with the ruling. The International Agency for Research on Cancer — a World Health Organization body — independently classified glyphosate as probably carcinogenic to humans. That finding stands. And a study that had supported the industry’s safety position was retracted by the scientific journal that published it in 2000 — a fact that feeds directly into fraud and scientific-manipulation theories that are not label-dependent and may survive preemption. The EPA said one thing. The world’s leading cancer authority said another. A court decided the EPA’s position means the label cannot carry a cancer warning. That is a labeling decision, not a scientific conclusion.
Alternative Legal Theories That May Survive the Ruling
The ruling foreclosed failure-to-warn claims. But the law of product liability has always contained multiple doors, and the Supreme Court closed only one. Here is what remains open, and how each theory connects to the evidence.
Design defect. A design defect claim argues that Roundup was defectively designed because safer alternative formulations were available or feasible — that the product itself, as formulated, was unreasonably dangerous. This theory is not label-dependent. It challenges the product formulation, not the label content. If a plaintiff can show that a safer glyphosate formulation existed or was technologically achievable, and that the company chose not to pursue it, that claim does not require a different warning on the label and may survive preemption. The evidence here lives in internal corporate research and development records, patent filings, formulation studies, and any documents showing the company considered but rejected safer alternatives.
Negligent testing and research. This theory targets corporate conduct in the research and development process itself — not the label. The claim is that Monsanto failed to conduct adequate long-term testing of glyphosate’s carcinogenic potential, or that it willfully ignored evidence of carcinogenicity that its own scientists or independent researchers surfaced. Internal emails, research data, communications with the EPA regarding study design, and internal safety assessments that diverge from public representations are the discovery targets. If the company’s own scientists raised concerns that were suppressed or ignored, that is negligent testing — and it has nothing to do with whether the label carried a cancer warning.
Fraud and misrepresentation. Perhaps the most potent surviving theory. Fraud claims allege that the company misrepresented the safety of glyphosate to regulators, the scientific community, or the public — including allegations of ghostwriting scientific studies or manipulating the scientific literature. The retracted 2000 safety study is directly relevant here: if a study supporting the industry’s safety position was withdrawn by the journal that published it, the integrity of the research underlying the EPA’s assessment is itself called into question. Fraud claims are distinct from label-based failure-to-warn because they target what the company said and did outside the four corners of the label. Evidence includes internal documents showing ghostwriting, coordinated efforts to shape the scientific record, communications with EPA officials, and any discrepancy between what the company knew internally and what it represented publicly.
Concert of action and civil conspiracy. If multiple entities participated in a coordinated effort to suppress evidence of glyphosate’s carcinogenicity — the manufacturer, contracted researchers, industry trade groups, consultants — a civil conspiracy or concert-of-action theory may reach participants beyond the primary manufacturer. This theory is only viable if supported by internal corporate documents obtained through discovery, but those documents are precisely what the discovery process is designed to surface.
The generalist files a failure-to-warn complaint that gets dismissed. The firm that understood what the ruling actually did pivots immediately to the theories the ruling left untouched. That difference is the case.
Iowa’s Specific Exposure to This Ruling
Iowa is not a bystander in this story. This state is among the most agriculturally intensive in the nation, with widespread glyphosate application across corn and soybean operations that creates exposure pathways for farmers, applicators, and rural residents. Iowa has documented elevated cancer rates, particularly in agricultural counties, fueling ongoing public health concern about pesticide exposure. The state’s large farming population represents a significant concentration of individuals with long-term, repeated Roundup exposure — the demographic most affected by this ruling.
Muscatine, Iowa, hosts a glyphosate production facility. That plant creates both occupational exposure pathways for the workers who manufacture the chemical and community-level exposure pathways for the surrounding neighborhoods. Plant workers who handled glyphosate concentrates day after day, year after year, and later developed cancer have a distinct exposure profile from farmers who applied the finished product — and their cases require a different exposure reconstruction. The Muscatine plant is not a footnote. It is a specific, local source of exposure that makes this ruling acutely personal for that community.
Iowa’s legislature has been an active battleground for pesticide tort reform. A bill first proposed by Bayer in Iowa’s 2024 legislative session to limit lawsuits by Iowans seeking compensation for pesticide-related illnesses narrowly passed the state Senate but failed to advance through the House. The legislation sparked protests and fierce debate at the Iowa Capitol. The Iowa Department of Agriculture and Land Stewardship, along with major agricultural organizations, lobbied for the lawsuit limits, arguing the lawsuits could jeopardize farmers’ access to the popular weedkiller and threaten glyphosate production at the Muscatine plant. The Iowa Association for Justice lobbied against the limits.
“Today’s Supreme Court ruling guts the rights of Roundup victims to seek justice in court. This hands liability immunity to a foreign corporation and rewards bad actors. But this does not have to be the final word.”
That public response from the Iowa Association for Justice captures both the severity of the blow and the refusal to treat it as the end. Both major candidates for Iowa governor — one aligned with the “Make America Healthy Again” movement, the other a Democrat — criticized the ruling. One called it a “terrible decision” and noted that farmers have lost their ability to have recourse when they are harmed. The other called it “wrong, gross” and said no immunity should be granted to chemical companies sickening Iowans. That bipartisan opposition is unusual, and it signals that the political landscape in Iowa is not settled. Congressional or state legislative action could reopen litigation avenues, though that cannot be predicted with confidence.
The Corporate Defendant: Bayer AG and Monsanto
Bayer AG is the German multinational pharmaceutical and life-sciences corporation that acquired Monsanto Company in 2018. Monsanto is the original developer, manufacturer, and marketer of glyphosate-based Roundup. Monsanto remains the named defendant in thousands of cancer lawsuits. Bayer argued and obtained the preemption defense before the Supreme Court. Both entities remain potential defendants under non-preempted theories.
The corporate structure matters because it affects who you sue and where the money is. Bayer is the deep-pocket parent. Monsanto is the subsidiary whose internal corporate knowledge of carcinogenicity research is the central discovery target. Distributors and retailers of Roundup products may face strict product liability claims under alternative theories not predicated on label warnings, though preemption analysis may extend to some downstream defendants. Custom applicators and commercial pesticide services who applied Roundup for agricultural or commercial purposes may face negligence claims if alternative exposure or handling theories are viable independent of label warnings.
What we look for inside Bayer and Monsanto is not the label. It is the paper trail behind the label. Internal emails between scientists and executives. Research data that was collected but never published. Communications with the EPA regarding study design and label warnings. Internal safety assessments that diverge from the company’s public representations. Evidence of ghostwriting — where the company drafted or shaped scientific studies that were then published under the names of independent academics. The retracted 2000 study and the editorial correspondence surrounding it. Each of these is a potential building block for fraud, negligent testing, or design defect claims that do not depend on what the label said.
The company’s CEO said the decision “brings overdue justice” and “provides the regulatory clarity necessary for innovators.” That is a public statement from the defendant’s leadership. What we want to see is whether the internal documents tell the same story the CEO told the public — or a different one.
The Evidence Clock: What Records Exist and How Fast They Disappear
Every toxic tort case is a race between the statute of limitations and the destruction of evidence. The ruling did not change that. It made it more urgent, because building the surviving theories — design defect, fraud, negligent testing — requires more documentary evidence than a failure-to-warn claim did. Here is what exists, who holds it, and how fast it can legally die.
Your medical records. Your cancer diagnosis, treatment history, and pathology are permanent in medical systems — but they should be compiled immediately to establish a baseline timeline. The specific cancer type matters. Non-Hodgkin lymphoma is the cancer most commonly associated with glyphosate exposure in the litigation, but other lymphomas and hematologic cancers have been alleged. Your oncologist’s records, your pathology reports, your chemotherapy and treatment records, your imaging — these are the foundation of the injury proof. They do not disappear, but they need to be assembled and organized into a coherent medical narrative that connects your diagnosis to your exposure history.
Your exposure history. This is where time is the enemy. Work records, purchase receipts, application logs, acreage treated, the years you used Roundup, the frequency, the method of application — all of this establishes specific causation by documenting the duration, frequency, and intensity of your Roundup exposure. This evidence degrades rapidly. Memories fade. Employers go out of business. Co-workers who could corroborate your exposure pass away or move. Purchase records are discarded under normal retention policies. Application logs from custom applicator services may be destroyed on short retention cycles. The day you call a lawyer is the day we start building this record — through sworn statements, corroborating witnesses, and documentary reconstruction — before the people who remember are gone.
Internal corporate documents from Monsanto and Bayer. Emails, research data, regulatory communications, ghostwriting evidence — these support the alternative theories of fraud, negligent testing, and design defect by showing corporate knowledge of carcinogenicity. These are subject to corporate retention policies and potential spoliation. They must be targeted through immediate discovery and litigation holds. A company that destroys documents after receiving a preservation demand faces sanctions and adverse-inference instructions — where the jury may assume the lost records were as bad as the plaintiff says. But a company that quietly lets records expire on their retention schedule before anyone asks for them faces no consequence at all. That is why the preservation letter goes out the day you call, not after months of deliberation.
EPA registration files and regulatory correspondence. These establish the regulatory framework and the timeline of what warnings were or were not approved. They are available through agency records, but administrative retention limits and FOIA backlogs create delays. Pull them early.
The IARC monograph and peer-reviewed scientific literature. The IARC classification of glyphosate as probably carcinogenic is permanent in the scientific record. It must be curated for expert admissibility under the applicable evidentiary standards. The conflict between IARC’s assessment and the EPA’s is not a problem for your case — it is the heart of your case.
The retracted 2000 safety study. The fact that a study supporting the industry’s safety position was retracted by the journal that published it supports fraud and scientific-manipulation theories. Journal archives may have limited retention of the editorial correspondence surrounding the retraction. The surrounding correspondence may be discoverable from the company. Pull it before it is gone.
The pattern is the same as in every toxic tort case: the fastest-dying evidence is the evidence closest to the individual — exposure memories, work records, witness availability. The corporate documents survive longer but are behind walls that only a lawsuit can breach. The gap between what is disappearing and what is locked away is where the urgency lives.
The Medicine: Cancer, Treatment, and the Long Arc
Roundup cancer cases typically involve catastrophic damages. The cancer type most commonly associated with glyphosate exposure in the litigation is Non-Hodgkin lymphoma, a cancer of the lymphatic system. Other hematologic cancers have been alleged in various cases. The treatment pathway for these cancers can be brutal and expensive.
Chemotherapy is typically the first-line treatment. Radiation therapy may follow, depending on the cancer type and stage. Surgical intervention may be necessary in certain cases. For aggressive or relapsed cases, a bone marrow transplant — also called a stem cell transplant — may be required, a procedure that involves weeks of hospitalization, a profoundly compromised immune system, and a recovery period measured in months to years. Ongoing oncological monitoring continues for life, because remission is not cure, and recurrence is always a possibility. In fatal cases, the damages include wrongful death losses — the financial support the deceased would have provided, the companionship lost, the funeral costs, the conscious pain and suffering before death.
Economic damages encompass medical expenses that can reach hundreds of thousands of dollars for cancer treatment alone. A bone marrow transplant can cost well into six figures. Lost wages during treatment and recovery. Diminished earning capacity if the cancer or its treatment leaves the patient unable to return to the same work. Future care costs for ongoing monitoring, medication, and treatment of complications. For an Iowa farmer, the lost earning capacity calculation includes not just wages but the value of the farming operation — the crops not planted, the livestock not tended, the business that may not survive the illness.
Non-economic damages include physical pain and suffering, which for cancer patients can be severe and prolonged. Emotional distress — the terror of a cancer diagnosis, the anxiety of treatment, the depression that often accompanies chronic illness. Loss of quality of life — the activities abandoned, the time with family stolen, the simple pleasures of an Iowa life that cancer interrupted. For wrongful death claims, the family loses consortium, society, and support.
The defense will exploit the latency problem. Cancer does not appear overnight. The latency period between glyphosate exposure and a cancer diagnosis can be years or even decades. The defense argues that the plaintiff cannot prove this cancer came from Roundup rather than from some other cause — background exposure, genetic predisposition, lifestyle factors. The counter requires dose reconstruction from exposure history, the epidemiological literature on glyphosate and cancer, the IARC classification, and expert testimony in oncology, toxicology, and epidemiology. The toxic tort lawyer who understands latency and discovery rules is the one who keeps these cases alive.
What a Case Is Worth After This Ruling
We will be honest with you about what the ruling did to case values, because honesty is what a grieving or frightened person needs from a lawyer, not a sales pitch.
The failure-to-warn theory, now blocked by the Supreme Court’s FIFRA preemption ruling, effectively zeroes out recovery under that theory for new cases and many pending cases. That is the floor: $0, if your case can only proceed on failure-to-warn and the ruling applies to it.
The high end reflects potential recovery under alternative theories — design defect, negligent testing, fraud — for a plaintiff with documented Non-Hodgkin lymphoma or another associated cancer plus a significant long-term Roundup exposure history. In that scenario, a case value reaching toward $1,500,000 is conceivable, though these theories are largely untested post-ruling and face uncertain preemption challenges. Iowa’s lack of statutory caps on compensatory damages is an advantage here — the full measure of proven economic and non-economic losses is recoverable, with no legislative ceiling cutting the number down.
Prior Roundup verdicts before this ruling were substantial, but they are not predictive of post-ruling outcomes. Those verdicts were built on failure-to-warn theories that the Supreme Court has now foreclosed. The landscape has changed. What a case is worth now depends on whether the alternative theories can be proven, and that depends on the evidence — the internal corporate documents, the exposure history, the medical records, and the expert testimony that ties them together.
Iowa’s modified comparative negligence system with a 51% bar means that if you are found to be 51% or more at fault, you cannot recover. If you are 50% or less at fault, your recovery is reduced by your percentage of fault. The defense will try to pin fault on the plaintiff — arguing that you used the product voluntarily, that you could have worn protective equipment, that you ignored instructions. Every percentage point they assign to you is money. This is why building the exposure record and the corporate-knowledge record matters so much: the more the jury sees about what the company knew and hid, the less room there is to blame the farmer.
In fatal cases, wrongful death claims carry the full weight of the loss — the financial support the deceased would have provided, the companionship, the guidance, the life that was taken. Iowa does not cap these damages. That matters.
The Defense Playbook and How We Counter Each Move
The defense has a playbook for Roundup cases, and the Supreme Court ruling just handed them the opening move. Here is what they will do, and here is how each play is countered.
Play 1: “The Supreme Court ruled for us — you cannot sue.” This is the broadest and most misleading version of the defense. The ruling blocked failure-to-warn claims based on label content under FIFRA preemption. It did not block design defect, negligent testing, fraud, or civil conspiracy claims. The counter is to reframe the complaint around the corporate conduct the ruling left untouched — the testing the company did not do, the science it may have manipulated, the safer formulation it chose not to pursue.
Play 2: “The EPA says glyphosate is safe.” The EPA found glyphosate unlikely to cause cancer. But the IARC — the World Health Organization’s cancer authority — classified it as probably carcinogenic. And the study supporting the industry’s safety position was retracted by the journal that published it. The counter is the scientific conflict itself: two authoritative bodies reached opposite conclusions, and the integrity of the research underlying the EPA’s assessment is questioned by the retraction. The EPA’s assessment is not the last word in science, and the Supreme Court’s ruling on labeling is not a ruling on science either.
Play 3: “You cannot prove your cancer came from Roundup.” The latency and multiple-causation argument. The defense will argue that cancer is common, that it has many causes, and that the plaintiff cannot isolate glyphosate as the specific cause. The counter is dose reconstruction — building a documented history of the duration, frequency, and intensity of Roundup exposure — combined with the epidemiological literature, the IARC classification, and expert testimony in oncology and toxicology that connects the exposure to the disease. This is harder without failure-to-warn, but it is not impossible, and it is exactly what the alternative theories are designed to do.
Play 4: Delay aimed at the statute of limitations. Iowa’s statute of limitations for personal injury and wrongful death claims generally runs two years from the date of discovery of the injury — the date you knew or should have known that you had cancer and that it might be connected to glyphosate exposure. For toxic tort cases with long latency, the discovery rule is critical: the clock starts when the connection becomes known, not when the exposure happened. But the defense will try to run that clock out by encouraging delay, by telling you to “wait and see” how the law develops, by making the case seem hopeless so you do not file in time. The counter is to act now. The deadline is real. The alternative theories are available. The evidence is dying.
Play 5: Quick settlement at low value. The defense may offer a fast, small settlement — designed to close the file cheaply before you understand what your case could be worth under the surviving theories. The counter is to never accept a settlement without a full evaluation of the design defect, fraud, and negligent testing claims — and without understanding the full measure of your damages, including future medical care, lost earning capacity, and non-economic losses.
Lupe Peña, our associate attorney, spent years inside a national insurance-defense firm before joining this side of the table. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows the Colossus valuation software, the IME-doctor selection process, the surveillance tactics, and the delay strategies from the inside. He now uses that knowledge for injured clients. That experience is exactly what a post-ruling Roundup case requires — someone who knows how the other side values the claim and where the pressure points are.
How a Case Is Actually Built After This Ruling
Here is the chronological walk of how a Roundup cancer case is built on the surviving theories, from the day you call to the day a number is on the table.
Week one. The preservation letter goes out — to Bayer, to Monsanto, to any custom applicator who applied Roundup on your behalf, to any employer whose records document your exposure. The letter orders them to freeze every email, every internal memo, every research file, every regulatory communication, every draft study, every editorial correspondence. It demands the EPA registration file history. It demands the IARC-related internal communications. It names the retracted study and demands the surrounding correspondence. This letter is the firewall against spoliation. Once it is on file, any document the company destroys is potential evidence of consciousness of guilt.
Weeks two through four. Medical records are compiled — the diagnosis, the pathology, the treatment history, the imaging, the oncologist’s notes. Exposure history is reconstructed through sworn statements, work records, purchase receipts, co-worker testimony, and agricultural application logs. The goal is a documented timeline of how long you used Roundup, how often, in what quantities, and by what method.
Months one through three. Experts are retained — an oncologist who can testify about the cancer type and its relationship to glyphosate exposure, a toxicologist who can reconstruct the dose and explain the mechanism, an epidemiologist who can tie the exposure to the disease at the population level, an agricultural exposure assessment expert who can quantify the exposure pathway, and a regulatory science expert who can explain the IARC-EPA conflict.
Months three through twelve. Discovery — the legal process that forces the company to produce the internal documents. This is where the fraud and negligent testing theories are built or broken. The depositions follow, where the company’s scientists and executives explain their choices under oath. The internal emails that show what they knew and when. The research data that was collected but never published. The communications with ghostwriters. The discrepancy between internal knowledge and public representations.
The number. At the end, the damages are built by a life-care planner who prices out the future medical care, a forensic economist who reduces the lost earnings and future costs to present value, and the non-economic losses that no spreadsheet can capture — the pain, the fear, the lost years, the stolen harvests, the family that will never be the same. The number is built from all of it. The Supreme Court ruling made the path to that number harder. It did not make it impossible.
Your First Steps: What to Do Right Now
If you are an Iowan who has been diagnosed with cancer after significant Roundup exposure — whether you are a farmer, a custom applicator, a plant worker in Muscatine, or a rural resident exposed through drift or water — here is what you should do and what you should refuse to do.
Document your exposure history now. Write down every job where you used or were around Roundup. The years. The frequency. The volume. The method of application — did you spray it yourself, did a custom applicator spray it, did you work in a facility that manufactured it? Keep purchase receipts, application logs, employment records, any paper that connects you to glyphosate. Memories fade. Co-workers move. Records are discarded. The day you start writing this down is the day the evidence starts surviving.
Compile your medical records. Request copies of your cancer diagnosis, pathology reports, treatment records, and all oncological correspondence. These are permanent in medical systems, but assembling them now establishes a clean baseline timeline.
Do not sign anything from Bayer, Monsanto, or any insurance company. A release or settlement agreement presented to you now — in the immediate aftermath of the ruling, when the defense hopes you are discouraged — is designed to close your file cheaply. Do not sign without speaking to a qualified toxic tort attorney.
Do not give a recorded statement. The friendly call from an insurance adjuster asking you to “just tell us what happened” is engineered to be quoted against you. You are not required to give a recorded statement to the other side’s insurance company.
Do not post about your case on social media. Surveillance and social-media mining are standard defense tactics in personal injury and toxic tort cases. Anything you post can be used to minimize your claim.
Call qualified counsel promptly. Iowa’s statute of limitations generally runs two years from the date of discovery — the date you knew or should have known that your cancer was connected to glyphosate exposure. The alternative legal theories that survive the Supreme Court ruling require more evidence and more time to develop than the failure-to-warn claims that were blocked. Waiting costs you evidence, witnesses, and time on the clock. The consultation is free. Call 1-888-ATTY-911.
Frequently Asked Questions
Can I still sue Monsanto or Bayer after the Supreme Court ruling?
Yes, potentially — but not on the same theory that was blocked. The ruling foreclosed failure-to-warn claims based on the product label under FIFRA preemption. Design defect claims, negligent testing claims, fraud and misrepresentation claims, and civil conspiracy claims target corporate conduct that is not label-dependent and may survive. Whether your specific situation supports a non-preempted claim depends on the facts and must be evaluated by qualified counsel.
Does the Supreme Court ruling mean Roundup is safe?
No. The ruling is a labeling and preemption decision, not a scientific finding. The EPA assessed glyphosate as unlikely to cause cancer. The International Agency for Research on Cancer — a World Health Organization body — independently classified glyphosate as probably carcinogenic to humans. That scientific conflict remains unresolved. A study supporting the industry’s safety position was retracted by the journal that published it. The ruling means the EPA’s assessment controls what goes on the label — it does not mean the science is settled.
I am an Iowa farmer who used Roundup for years and was diagnosed with Non-Hodgkin lymphoma. Is my case over?
Not necessarily. Your failure-to-warn claim is likely blocked by the ruling, but if your exposure history is documented and significant, alternative theories — particularly design defect and fraud — may be viable. The key is to act quickly to preserve your exposure evidence and medical records and to have your case evaluated for the surviving theories before the statute of limitations runs.
I worked at the glyphosate plant in Muscatine. Does this ruling affect my case?
The ruling affects any failure-to-warn claim against Monsanto or Bayer related to an EPA-regulated pesticide label. Plant workers have a distinct exposure profile from farmers — occupational exposure to glyphosate concentrates in a manufacturing setting — and the specific causation analysis is different. Your case may still proceed on alternative theories. Document your work history, your job duties, the years you worked at the plant, and your medical diagnosis.
How long do I have to file a Roundup cancer lawsuit in Iowa?
Iowa’s statute of limitations for personal injury and wrongful death claims generally runs two years from the date of discovery — the date you knew or should have known that your injury was connected to glyphosate exposure. For toxic tort cases with long latency periods, the discovery rule is critical. But this deadline is state-specific and can be affected by many factors. Do not assume you have plenty of time. Talk to a lawyer who can evaluate your specific deadline.
What if I already have a Roundup lawsuit filed — does this ruling dismiss my case?
The ruling is expected to block thousands of pending failure-to-warn lawsuits. If your pending case is built solely on failure-to-warn, it may be dismissed or you may be given an opportunity to amend your complaint to assert surviving theories. This depends on the procedural posture of your case, the court’s approach to the ruling, and the specific claims pleaded. If you have an existing case, your current counsel should be evaluating the ruling’s impact immediately. If you need a second evaluation, call us.
Could Congress or the Iowa legislature change the law and reopen these cases?
The Iowa Association for Justice has said this “does not have to be the final word” and has indicated that the law the Supreme Court relied on was written by Congress and can be changed by Congress. Iowa’s own legislature considered but failed to pass a bill that would have shielded pesticide companies from similar tort claims, and both major gubernatorial candidates opposed shielding pesticide companies. Legislative action could potentially reopen litigation avenues, but it cannot be predicted with confidence and cannot be relied upon. The safest approach is to pursue the surviving legal theories now, not to wait for a legislative fix.
What is my Roundup cancer case worth now?
The honest range after this ruling is wide. If your case can only proceed on failure-to-warn, the ruling likely reduces its value to zero. If your case can proceed on design defect, fraud, or negligent testing theories, and you have documented cancer plus significant exposure history, the value could reach toward $1,500,000 or more — though these theories are largely untested post-ruling. Iowa does not cap compensatory damages, which is an advantage. The value depends on the strength of the alternative theories, the evidence, the specific cancer and its treatment costs, and the exposure documentation. Past results depend on the facts of each case and do not guarantee future outcomes.
Why should I call Attorney911 instead of just giving up?
Because the ruling closed one door and left others open, and the difference between a case that survives and a case that dies is whether someone reads the ruling carefully enough to find those other doors. We take toxic tort cases in Iowa. We understand FIFRA preemption and what it does and does not reach. We know how to build fraud and negligent testing claims from corporate documents. We know the Iowa statute of limitations and the discovery rule. And we know that the evidence in these cases — your exposure history, the corporate paper trail, the witness memories — is dying on a clock that does not care about the Supreme Court. The consultation is free. We do not get paid unless we win. Call 1-888-ATTY-911.
Who We Are and Why It Matters for Your Roundup Case
Ralph Manginello is the managing partner of our firm. He has been licensed for 27+ years, admitted to practice in federal court, and was a journalist before he was a lawyer — which means he knows how to find the document the company does not want found. He handles the catastrophic-injury and wrongful-death cases that demand a trial lawyer who has spent decades in courtrooms. He speaks Spanish.
Lupe Peña is our associate attorney. He is a former insurance-defense attorney who spent years inside a national defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue people exactly like you. He knows claim valuation from the inside. He knows how the other side picks its IME doctors, runs its surveillance, and engineers its recorded-statement traps. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. He now uses everything he learned on the defense side to fight for injured clients.
We take Iowa cases. We are based in Texas and work with local counsel in Iowa as required — we do not claim an office in Iowa or an Iowa bar admission, and we will tell you that plainly. What we bring is the experience, the resources, and the willingness to build a case on the theories the Supreme Court left alive. We handle toxic tort, mass tort, and wrongful death cases. The firm has recovered more than $50 million for clients across its practice. Past results depend on the facts of each case and do not guarantee future outcomes.
The fee is contingency: 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free. The call is confidential. Our staff is live 24 hours a day, 7 days a week — not an answering service. Hablamos Español.
If the Supreme Court ruling made you think your case was over, call us before you decide that. The ruling changed the path. It did not change the underlying injustice — the cancer, the exposure, the years of handling a product that one of the world’s leading cancer authorities says is probably carcinogenic. The path is harder now. It is not closed. Call 1-888-ATTY-911 or contact us. We will tell you honestly whether your situation supports a surviving claim, and if it does, we will tell you exactly what happens next.